Compare Enveric Biosciences Inc (ENVB) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Southern Copper Corp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Southern Copper Corp trades at $204 (market cap $167.74B). The key difference: Southern Copper Corp is far larger — about 24667.6× Enveric Biosciences Inc's market cap, and Southern Copper Corp pays a 2.21% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Southern Copper Corp for 61 Days on average.
| ENVB | SCCO | |
|---|---|---|
Market Cap | $6.80M | $167.74B |
Volume | 64,867 | 853,110 |
Sector | Health | Basic Materials |
52-Week High | $10.80 | $219.70 |
52-Week Low | $1.27 | $120.02 |
Typical Hold Time | 14 Days | 61 Days |
Enterprise Value | -$1.49M | $169.03B |
Dividend Yield | — | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
SCCO trades at $200.57, down 1.81% on the day, with technical indicators showing neutral momentum. The company demonstrates strong fundamentals with revenue growth from $13.42B in 2025 to projected $15.8B in 2026 and impressive profitability margins including 35.87% net income margin. Recent earnings beats and a $10.2B Mexican project pipeline support growth prospects, though the stock trades at premium valuations with P/E of 30.1 and P/S of 10.82.
While SCCO's operational strength and copper demand from AI infrastructure provide upside potential, the stock faces headwinds from its premium valuation relative to peers and mixed analyst sentiment with only 10.34% buy ratings. The current price sits above the consensus target of $167.67, suggesting limited near-term upside despite strong cash flow generation and dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
